General Information
For each type of in vitro model:
- The origin of material used to generate a specific model is listed in the PDMR database with the model growth information.
- Complete human pathogen assessment has been performed as described in SOP50104. The PDMR does not distribute models that are positive for human immunodeficiency virus, Hepatitis B, or Hepatitis C.
- Human origin has been confirmed.
- STR profiles validated matching patient material and/or other models derived from the same patient material.
- Model-specific Certificate of Analysis is provided with distributed material.
- PDMR SOPs should be used to ensure culture success β these models should not be treated like traditional in vitro cultures (e.g., HeLa, MCF7).
For PDOrg and PDC models:
- Derived xenografts are confirmed by histopathology to match the patient diagnosis or pathology of patient originator material.
- Whole exome sequence and RNASeq data are available in the PDMR.
PDOrg Models
Guaranteed for at least 10 passages (following PDMR SOPs)
PDOrg Model Generation
- The PDMR generates PDOrg in vitro models from patient material and then PDXs (in that order of priority) to try to maximize model heterogeneity.
- PDOrg cultures use specialized defined media with growth supported in a basement membrane dome. The PDMR has noted 3 different morphological patterns of growth among PDOrgs: organoids, loose aggregate clusters, and single cell/small clusters.
PDOrg-Specific Quality Control
- Verified to be 99.9% human tumor culture, non-clonal (multiple cell types or non-cloned lineages), 99.9% fibroblast free (FACs analysis).
- Proven to grow as a cell-line derived xenograft (CLX) in NSG host mice. CLXs are characterized by histopathology for human tumor/diagnosis sub-type confirmation but are not further analyzed.
- No out-growth of fibroblasts has been observed for at least 10 passages.
- May or may not be able to form spheroids in a fully-defined, serum- and feeder-free medium
PDC Models
Guaranteed for at least 20 passages (following PDMR SOPs)
PDC Model Generation
- The PDMR generates PDC in vitro models from patient material, PDX, and patient/PDX-derived organoids (PDOrg) (in that order of priority) to try to maximize model heterogeneity.
- PDC cultures use defined media and grow with a variety of growth characteristics.
PDC-Specific Quality Control
- Verified to be 99.9% human tumor culture, non-clonal (multiple cell types or non-cloned lineages), 99.9% fibroblast free (FACs analysis).
- Proven to grow as a cell-line derived xenograft (CLX) in NSG host mice. CLXs are characterized by histopathology for human tumor/diagnosis sub-type confirmation but are not further analyzed.
- No out-growth of fibroblasts has been observed for at least 20 passages.
- Tested for growth as spheroids in fully-defined, serum- and feeder-free medium and tested for clonal growth in soft agar.
CAF Models
Guaranteed for at least 3 passages (following PDMR SOPs) and non-tumorigenic in mice
CAF Model Generation
- CAFs are primarily generated from patient material, though occasionally they can be recovered from a P0/P1 PDX.
- CAF cultures use defined Media and are grown on Matrigel-coated plates.
CAF-Specific Quality Control
- Verified to be 99.9% human fibroblast culture and 99.9% human tumor cell free by FACS analysis.
- These cultures have been proven to be non-tumorigenic following subcutaneous implantation into NSG mice and have been characterized as fibroblasts by at least one of the following methods: immunohistochemistry, qRT-PCR, or FACs.
- It is important to note these are non-transformed cells. CAFs have a finite lifespan in vitro.
- CAFs are guaranteed for experimental use for up to 3 passages when maintained on Matrigel-coated surface in the recommended defined media.
- Additional population doublings and subcultures are possible, but overall fitness of culture may deteriorate with subsequent passages.
- Not sequenced for the Repository, though they may be used as a germline surrogate for the model.